The first half of 2026 has seen active U.S. Food and Drug Administration (FDA) enforcement across multiple regulatory domains. For regulated companies, monitoring the FDA’s enforcement priorities is critical to compliance and audit readiness.
Megan Robertson, Member of the Firm, examines the FDA’s recent enforcement actions, identifies six trends in the agency’s regulatory approach, and offers practical guidance for in-house counsel.
A journalist who spread false information about the family of then-presidential candidate Lee Jae Myung ahead of the 21st presidential election was fined. The Dae-gu District Court Andong Branch C...